Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients with Krabbe Disease.
– FBX-101 clinical data demonstrates safety and initial efficacy from the RESKUE trial
– FBX-101 is a systemic AAV gene therapy following unrelated cord blood transplantation (“UCBT”) and has been well tolerated through Day 180
– FBX-101 significantly increased GALC enzyme activity in leukocytes and patient exhibited improved motor function and normal brain development
To read the full press release: Full Press Release 30.08.22